Sun Healthcare Group, Inc. (NASDAQ:SUNH), RADVISION LTD. (NASDAQ:RVSN), Broadvision (NASDAQ:BVSN), Meru Networks Inc. (NASDAQ:MERU), Essex Rental Corporation (NASDAQ:ESSX), Elecsys Corp. (NASDAQ:ESYS) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) were the biggest gainers on the NASDAQ, Monday, December 12.
Sun Healthcare Group, Inc. (SUNH) ended the session up 17.52 percent, closing at $3.69. They traded in a range of $3.07 to $3.72. A total of 985,686 shares changed hands.
RADVISION LTD. (RVSN) ended the session up 12.83 percent, closing at $8.18. They traded in a range of $7.45 to $9.98. A total of261,834 shares changed hands.
Broadvision (BVSN) ended the session up 11.95 percent, closing at $9.18. They traded in a range of $8.23 to $9.25. A total of 189,065 shares changed hands.
Meru Networks Inc. (MERU) ended the session up 11.84 percent, closing at $4.25. They traded in a range of $3.71 to $4.27. A total of 349,047 shares changed hands.
Essex Rental Corporation (ESSX) ended the session up 11.74 percent, closing at $2.76. They traded in a range of $2.46 to $3.08. A total of 74,837 shares changed hands.
Elecsys Corp. (ESYS) ended the session up 9.76 percent, closing at $4.50. They traded in a range of $3.95 to $4.50. A total of 11,536 shares changed hands.
Arena Pharmaceuticals, Inc. (ARNA) ended the session up 9.00 percent, closing at $2.18. They traded in a range of $1.96 to $2.25. A total of 5,046,501 shares changed hands.
Showing posts with label Arena Pharmaceuticals. Show all posts
Showing posts with label Arena Pharmaceuticals. Show all posts
Tuesday, December 13, 2011
Monday, March 7, 2011
Arena Pharma (ARNA), SunTech Power (STP), DryShips (DRYS), Molycorp (MCP) Reporting This Week
A diverse set of companies will be closing down the earnings season, as Arena Pharma (ARNA), SunTech Power (STP), DryShips (DRYS) and Molycorp (MCP) will post results this week.
This will be against the backdrop of uncertainty concerning oil prices, which will be watched closely as to how it will impact the overall economy and market.
There will be a number of retailers finishing off the earnings season as well, with Aeropostale (ARO), American Eagle Outfitters (AEO), AnnTaylor (ANN) and Urban Outfitters (URBN), among others, set to report.
Molycorp closed Friday at $49.26, down $0.57, or 1.14 percent. They've been a beneficiary of the decision by the Chinese that they were going to cut back on rare earths exports.
Dryships closed at $5.04, level with the close of the session before. Suntech Power closed Friday at $9.43, losing $0.06, or 0.63 percent. Arena Phama dropped to $1.58, falling $0.03, or 1.86 percent.
This will be against the backdrop of uncertainty concerning oil prices, which will be watched closely as to how it will impact the overall economy and market.
There will be a number of retailers finishing off the earnings season as well, with Aeropostale (ARO), American Eagle Outfitters (AEO), AnnTaylor (ANN) and Urban Outfitters (URBN), among others, set to report.
Molycorp closed Friday at $49.26, down $0.57, or 1.14 percent. They've been a beneficiary of the decision by the Chinese that they were going to cut back on rare earths exports.
Dryships closed at $5.04, level with the close of the session before. Suntech Power closed Friday at $9.43, losing $0.06, or 0.63 percent. Arena Phama dropped to $1.58, falling $0.03, or 1.86 percent.
Wednesday, December 22, 2010
Arena (Nasdaq:ARNA) Crushed on Uncertainty Surrounding Lorcaserin
Arena (Nasdaq:ARNA) is getting hammered today at the volatile stock continues its ways, based on the rejection of its diet pill lorcaserin rejected by the FDA.
While the company will submit a new application near the end of 2011, probability of approval appears increasingly dim, not only because of the obvious concerns over tumors discovered in mice during studies, but also with the comment from an FDA drug expert advisers who said its questionable as to the effectiveness of the drug itself in relationship to weight loss.
Together this doesn't present a good narrative for the company or shareholders going forward, although traders will enjoy the volatility of the stock as it bounces around on every bit of news that comes out about it.
Taking into account safety issues and dubious effectiveness, Arena is in for a long struggle to get approval for Lorcaserin, if they ever do.
Arena Pharmaceuticals was trading at $1.82, down $0.22, or 10.78 percent, as of 1:51 PM EDT.
While the company will submit a new application near the end of 2011, probability of approval appears increasingly dim, not only because of the obvious concerns over tumors discovered in mice during studies, but also with the comment from an FDA drug expert advisers who said its questionable as to the effectiveness of the drug itself in relationship to weight loss.
Together this doesn't present a good narrative for the company or shareholders going forward, although traders will enjoy the volatility of the stock as it bounces around on every bit of news that comes out about it.
Taking into account safety issues and dubious effectiveness, Arena is in for a long struggle to get approval for Lorcaserin, if they ever do.
Arena Pharmaceuticals was trading at $1.82, down $0.22, or 10.78 percent, as of 1:51 PM EDT.
Subscribe to:
Posts (Atom)